The worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to .7 billion in 2017. The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more effective and tolerable pipeline agents.
Therapy Trends Consensus Outlook: Hepatitis C provides an in-depth analysis of the products players and events that will shape the future HCVmarket.
Therapy Trends Consensus Outlook: HIV includes the following comprehensive resources:
Therapy Trends Consensus Outlook: Hepatitis C provides:
Forecast analysis report and data model
The forecast analysis report component of Consensus Outlook: Hepatitis C delivers a rich analysis of product-level sales forecast data and of the future events that underpin the forecasts. The product of meticulous FirstWord research, its historical sales data (2007–12) is based on company information, and the five-year (2013-17) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
The report combines independent, unbiased, accurate forecasts with invaluable insights into factors that impact future product performance, backed-up by research of analysts who have an unrivalled level of intimacy with the market, the players, their products and their strategies.
FirstWord’s HCV forecast data model allows to you examine detailed Excel spreadsheets to quickly compare various market parameters.
Stay a step ahead with Therapy Trends Consensus Outlook updates. Over the next 12 months, you will receive updated market analysis and forecast reports each time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.
For each Therapy Trends report, FirstWord analysts produce a data analysis modulea Consensus Outlookwhich provides annual historical and forecast product-level sales data. Historical sales data is derived from company information, while the five-year (2012-2017) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.
Once a Therapy Trends data module is published, FirstWord analysts subsequently collate and evaluate the latest relevant reports published by equity research analysts and feed relevant updated forecasts into the Therapy Trends forecast model.
Consensus forecasts derived from the leading equity research analysts reflect the most up-to-date assessment of the pharmaceutical market, with equity analyst models updated to reflect a broad spectrum of events and catalysts, which range from the publication of quarterly financial results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections–produced either internally or by other third parties–can be assessed.
Equity research teams utilize a selection of analytical frameworks to generate product level forecasts, focusing heavily on patient and event based modelling. In addition to consensus forecasting, FirstWord Therapy Trend data modules also collate and analyse the key future events that are anticipated to impact product level forecasts and shape the broader context of a specific disease area – to produce a ‘consensus calendar’ of events designed to help inform FirstWord clients on how the market will evolve.
Leading equity research analysts have a deep intimacy with the prescription pharmaceutical market and the companies they cover; supported by unrivalled research resources, this highly analytical insight extends to the product franchises of these companies (driven by a ‘bottom-up’ forecasting methodology) and the strategic protocols being pursued by company management.
Table of Contents
for Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
1.Hepatitis C Marketplace
2.Key Hepatitis C Developers
3.Hepatitis C Class Dynamics
4. (sofosbuvir (GS-7977, Gilead) forecast
5.Olysio (simeprevir; Medivir/Tibotec) forecast
6.Incivek (telaprevir; Vertex Tibotec/Mitsubishi Tanabe) forecast
7.Victrelis (boceprevir; Merck) forecast
8.PegaSys (pegylated interferon-alpha; Roche) forecast
9.PegIntron (pegylated interferon-alpha; Merck) forecast
10.Abbott franchise (ABT-333/ABT-450/ABT-267; Abbott) forecast
11.Bristol-Myers Squibb franchise (daclastasvir/asunaprevir) forecast
12.Sovaprevir (ACH-1625; Achillion Pharmaceuticals) forecast
13.MK-5172 (Merck) forecast
14.Vaniprevir (MK-7009; Merck) forecast
15.VX-222 (Vertex) forecast
|Title||Date Published||Price from||More Details|
|Global Hepatitis Partnering 2010 to 2016|
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
|01 Oct 2016 by Current Partnering||USD $1,495||More Info|
|Hepatitis C: Update Bulletin [February 2016]|
IntroductionGain new KOL insights on the latest events that have the potential to shape the hepatiti...
|01 Feb 2016 by FirstWord Pharma||USD $995||More Info|
|Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015|
Alcoholic Hepatitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report...
|16 Dec 2015 by Global Data||USD $2,500||More Info|
|Hepatitis C: KOL Insight|
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
|01 Sep 2015 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: The hepatitis C pricing war - what impact on prescribers?|
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
|29 Jan 2015 by FirstWord Pharma||USD $695||More Info|
|Payer Insights: Hepatitis C|
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
|26 Sep 2014 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?|
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
|08 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?|
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
|01 Apr 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?|
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
|01 Nov 2013 by FirstWord Pharma||USD $695||More Info|
|Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?|
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
|01 Oct 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.